Stocksigma LogoStocksigma Logo

Lupin Secures US FDA Approval for Amifampridine Tablets with 180-Day Shared Exclusivity

Lupin has received US FDA approval for its Abbreviated New Drug Application for Amifampridine Tablets, 10 mg, bioequivalent to Catalyst Pharmaceuticals'

Lupin Secures US FDA Approval for Amifampridine Tablets with 180-Day Shared Exclusivity

Lupin Ltd 路 Press Release 路 02 Nov 2026, 11:34 pm

Lupin Secures US FDA Approval for Amifampridine Tablets with 180-Day Shared Exclusivity Lupin has received US FDA approval for its Abbreviated New Drug Application for Amifampridine Tablets, 10 mg, bioequivalent to Catalyst Pharmaceuticals' reference listed drug, Firdapse Tablets, 10 mg. As one of the first ANDA applicants, Lupin is eligible for 180 days of shared generic exclusivity in the US market.

Original exchange filing (PDF)

More announcements from Lupin Ltd

All Lupin Ltd announcements